Skip to main content

Table 2 Pregnancy outcomes (proportion of adverse outcome to number of exposed pregnancies) of included studies

From: Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis

Outcomes Group

preterm delivery

low birth weight

spontaneous abortion

congenital malformations

A

B

A

B

A

B

A

B

Kiely CJ [17]

2/21

2/21

0/10

1/11a

0/21

Schnitzler F [18]

8/42

6/42

6/35

1/7

0/35

1/7

Seirafi M [19]

      

1/86

0/42

Casanova MJ [20]

      

0/20

1/9

Julsgaard M [21]

3/80

6/80

  

2/44

1/36

Arsenescu R [22]

    

1/8

0/2

0/10

Slama W [23]

    

1/122

1/64

3/122

1/64

Zelinkova Z [24]

    

1/18

2/13

1/18

0/13

  1. A: exposed to Infliximab B: exposed to Adalimumab
  2. aThis patient underwent an emergency colectomy following failed treatment with adalimumab. The stillbirth occurred at week 21 gestation, 11 days following the colectomy